Rigel Pharmaceuticals | RIGL - Trade Creditors


Rigel Pharmaceuticals reported $3.85M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
Agenus USD 58.98M 12.1M Jun/2026
Amgen USD 20.83B 17.97B Sep/2026
Anika Therapeutics USD 6.24M 103K Jun/2026
Arrowhead Research USD 27.78M 2.97M Jun/2026
AstraZeneca USD 23.57B 679M Sep/2026
BioMarin Pharmaceutical USD 946.11M 32.44M Sep/2026
Bristol-Myers Squibb USD 4.63B 470M Sep/2026
Celldex Therapeutics USD 11.24M 3.44M Sep/2026
Daiichi Sankyo JPY 612.24B 73.19B Sep/2026
Eli Lilly USD 5.79B 319M Sep/2026
Halozyme Therapeutics USD 33.55M 9.94M Sep/2026
Heron Therapeutics USD 8.38M 3.27M Sep/2026
Intrexon USD 4.85M 3.12M Jun/2024
Ionis Pharmaceuticals USD 27.11M 20.59M Sep/2026
Karyopharm Therapeutics USD 4.28M 276K Mar/2026
Ligand Pharmaceuticals USD 4.1M 5.31M Sep/2026
MacroGenics USD 3.44M 845K Jun/2026
Neurocrine Biosciences USD 754.1M 612.1M Sep/2026
Pfizer USD 4.07B 511M Sep/2026
Regeneron Pharmaceuticals USD 1.14B 19M Sep/2026
Rigel Pharmaceuticals USD 3.85M 3.44M Sep/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Ultragenyx Pharmaceutical USD 45M 6M Sep/2026
Veracyte USD 9.71M 1.69M Sep/2026